7452 related articles for article (PubMed ID: 1868046)
1. Unusual gastrointestinal complications of interleukin-2 therapy.
Rahman R; Bernstein Z; Vaickus L; Penetrante R; Arbuck S; Kopec I; Vesper D; Douglass HO; Foon KA
J Immunother (1991); 1991 Jun; 10(3):221-5. PubMed ID: 1868046
[TBL] [Abstract][Full Text] [Related]
2. Gastrointestinal perforations associated with interleukin-2 administration.
Heimann DM; Schwartzentruber DJ
J Immunother; 2004; 27(3):254-8. PubMed ID: 15076143
[TBL] [Abstract][Full Text] [Related]
3. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer.
Rosenberg SA; Lotze MT; Yang JC; Topalian SL; Chang AE; Schwartzentruber DJ; Aebersold P; Leitman S; Linehan WM; Seipp CA
J Natl Cancer Inst; 1993 Apr; 85(8):622-32. PubMed ID: 8468720
[TBL] [Abstract][Full Text] [Related]
4. Metastatic malignant melanoma treated with combined bolus and continuous infusion interleukin-2 and lymphokine-activated killer cells.
Bar MH; Sznol M; Atkins MB; Ciobanu N; Micetich KC; Boldt DH; Margolin KA; Aronson FR; Rayner AA; Hawkins MJ
J Clin Oncol; 1990 Jul; 8(7):1138-47. PubMed ID: 2358835
[TBL] [Abstract][Full Text] [Related]
5. Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma.
Sznol M; Clark JW; Smith JW; Steis RG; Urba WJ; Rubinstein LV; VanderMolen LA; Janik J; Sharfman WH; Fenton RG
J Natl Cancer Inst; 1992 Jun; 84(12):929-37. PubMed ID: 1629914
[TBL] [Abstract][Full Text] [Related]
6. Intraperitoneal lymphokine-activated killer-cell and interleukin-2 therapy for malignancies limited to the peritoneal cavity.
Steis RG; Urba WJ; VanderMolen LA; Bookman MA; Smith JW; Clark JW; Miller RL; Crum ED; Beckner SK; McKnight JE
J Clin Oncol; 1990 Oct; 8(10):1618-29. PubMed ID: 2213099
[TBL] [Abstract][Full Text] [Related]
7. Adoptive immunotherapy of patients with metastatic renal cell cancer using lymphokine-activated killer cells, interleukin-2 and cyclophosphamide: long-term results.
Tomita Y; Katagiri A; Saito K; Imai T; Saito T; Tanikawa T; Terunuma M; Nishiyama T; Takahashi K
Int J Urol; 1998 Jan; 5(1):16-21. PubMed ID: 9535595
[TBL] [Abstract][Full Text] [Related]
8. Interleukin 2 and lymphokine-activated killer cell therapy: analysis of a bolus interleukin 2 and a continuous infusion interleukin 2 regimen.
Clark JW; Smith JW; Steis RG; Urba WJ; Crum E; Miller R; McKnight J; Beman J; Stevenson HC; Creekmore S
Cancer Res; 1990 Nov; 50(22):7343-50. PubMed ID: 2224862
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II study.
Parkinson DR; Abrams JS; Wiernik PH; Rayner AA; Margolin KA; Van Echo DA; Sznol M; Dutcher JP; Aronson FR; Doroshow JH
J Clin Oncol; 1990 Oct; 8(10):1650-6. PubMed ID: 2213101
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines.
Margolin KA; Rayner AA; Hawkins MJ; Atkins MB; Dutcher JP; Fisher RI; Weiss GR; Doroshow JH; Jaffe HS; Roper M
J Clin Oncol; 1989 Apr; 7(4):486-98. PubMed ID: 2647914
[TBL] [Abstract][Full Text] [Related]
11. Activity of continuous infusion plus pulse interleukin-2 with famotidine in patients with metastatic kidney cancer or melanoma previously treated with interleukin-2.
Quan WD; Walker PR; Quan FM; Ramirez M; Elsamaloty HM; Ghai V; Vinogradov M; Liles DK
Cancer Biother Radiopharm; 2006 Oct; 21(5):437-42. PubMed ID: 17105418
[TBL] [Abstract][Full Text] [Related]
12. Colonic perforation. An unusual complication of therapy with high-dose interleukin-2.
Schwartzentruber D; Lotze MT; Rosenberg SA
Cancer; 1988 Dec; 62(11):2350-3. PubMed ID: 3263182
[TBL] [Abstract][Full Text] [Related]
13. Isolation perfusion in extracorporeal circulation with interleukin-2 and lymphokine-activated killer cells in the treatment of in-transit metastases from limb cutaneous melanoma.
Vaglini M; Belli F; Santinami M; Arienti F; Parmiani G; Persiani L; Santoro N; Grazia Inglese M; D'Elia F; Cascinelli N
Ann Surg Oncol; 1995 Jan; 2(1):61-70. PubMed ID: 7834457
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer.
Stewart JA; Belinson JL; Moore AL; Dorighi JA; Grant BW; Haugh LD; Roberts JD; Albertini RJ; Branda RF
Cancer Res; 1990 Oct; 50(19):6302-10. PubMed ID: 2205379
[TBL] [Abstract][Full Text] [Related]
15. Colosplenic fistula in a patient treated with interleukin-2 for malignant melanoma.
Chun ES; Demos TC; Gaynor ER
J Comput Assist Tomogr; 1997; 21(4):674-6. PubMed ID: 9216783
[TBL] [Abstract][Full Text] [Related]
16. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone.
Rosenberg SA; Lotze MT; Muul LM; Chang AE; Avis FP; Leitman S; Linehan WM; Robertson CN; Lee RE; Rubin JT
N Engl J Med; 1987 Apr; 316(15):889-97. PubMed ID: 3493432
[TBL] [Abstract][Full Text] [Related]
17. Therapy of advanced solid tumors in mice using chemotherapy in combination with interleukin-2 with and without lymphokine-activated killer cells.
Kedar E; Ben-Aziz R; Shiloni E
Isr J Med Sci; 1988; 24(9-10):494-504. PubMed ID: 3264551
[TBL] [Abstract][Full Text] [Related]
18. Laboratory correlates of adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells in humans.
Boldt DH; Mills BJ; Gemlo BT; Holden H; Mier J; Paietta E; McMannis JD; Escobedo LV; Sniecinski I; Rayner AA
Cancer Res; 1988 Aug; 48(15):4409-16. PubMed ID: 3260537
[TBL] [Abstract][Full Text] [Related]
19. Clinical and immunomodulatory effects of combination immunotherapy with low-dose interleukin 2 and tumor necrosis factor alpha in patients with advanced non-small cell lung cancer: a phase I trial.
Yang SC; Grimm EA; Parkinson DR; Carinhas J; Fry KD; Mendiguren-Rodriguez A; Licciardello J; Owen-Schaub LB; Hong WK; Roth JA
Cancer Res; 1991 Jul; 51(14):3669-76. PubMed ID: 1648441
[TBL] [Abstract][Full Text] [Related]
20. Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial.
Fisher RI; Coltman CA; Doroshow JH; Rayner AA; Hawkins MJ; Mier JW; Wiernik P; McMannis JD; Weiss GR; Margolin KA
Ann Intern Med; 1988 Apr; 108(4):518-23. PubMed ID: 3258138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
